临床医学工程
臨床醫學工程
림상의학공정
Clinical Medical & Engineering
2015年
11期
1451-1452
,共2页
氯吡格雷%阿司匹林%双重抗血小板治疗%急性脑梗死
氯吡格雷%阿司匹林%雙重抗血小闆治療%急性腦梗死
록필격뢰%아사필림%쌍중항혈소판치료%급성뇌경사
Clopidogrel%Aspirin%Dual antiplatelet therapy%Acute cerebral infarction
目的 观察阿司匹林与氯吡格雷双重抗血小板治疗急性脑梗死的临床效果. 方法 82例急性脑梗死患者随机分为两组各41例, 对照组单纯使用阿司匹林进行治疗, 观察组在此基础上联合氯吡格雷进行治疗, 比较两组的临床效果. 结果 治疗后观察组血清CRP水平及纤维蛋白原均显著低于对照组 (P <0.05). 观察组总有效率为95.1%, 显著高于对照组的75.6% (P <0.05). 治疗后观察组Berghel评分及NIHSS指数评分均显著低于对照组 (P<0.05). 结论 联合氯吡格雷与阿司匹林双重抗血小板治疗急性脑梗死, 可降低血清CRP水平及纤维蛋白原, 其疗效安全可靠, 值得临床应用及推广.
目的 觀察阿司匹林與氯吡格雷雙重抗血小闆治療急性腦梗死的臨床效果. 方法 82例急性腦梗死患者隨機分為兩組各41例, 對照組單純使用阿司匹林進行治療, 觀察組在此基礎上聯閤氯吡格雷進行治療, 比較兩組的臨床效果. 結果 治療後觀察組血清CRP水平及纖維蛋白原均顯著低于對照組 (P <0.05). 觀察組總有效率為95.1%, 顯著高于對照組的75.6% (P <0.05). 治療後觀察組Berghel評分及NIHSS指數評分均顯著低于對照組 (P<0.05). 結論 聯閤氯吡格雷與阿司匹林雙重抗血小闆治療急性腦梗死, 可降低血清CRP水平及纖維蛋白原, 其療效安全可靠, 值得臨床應用及推廣.
목적 관찰아사필림여록필격뢰쌍중항혈소판치료급성뇌경사적림상효과. 방법 82례급성뇌경사환자수궤분위량조각41례, 대조조단순사용아사필림진행치료, 관찰조재차기출상연합록필격뢰진행치료, 비교량조적림상효과. 결과 치료후관찰조혈청CRP수평급섬유단백원균현저저우대조조 (P <0.05). 관찰조총유효솔위95.1%, 현저고우대조조적75.6% (P <0.05). 치료후관찰조Berghel평분급NIHSS지수평분균현저저우대조조 (P<0.05). 결론 연합록필격뢰여아사필림쌍중항혈소판치료급성뇌경사, 가강저혈청CRP수평급섬유단백원, 기료효안전가고, 치득림상응용급추엄.
Objective To observe the effect of dual antiplatelet therapy with aspirin and clopidogrel for the treatment of acute cerebral infarction. Methods 82 patients with acute cerebral infarction were randomly divided into two groups, with 41 cases in each group. The control group was treated with aspirin, while the observation group was treated with aspirin and clopidogrel. The clinical effects of two groups were compared. Results After therapy, the serum CRP level, serum fibrinogen level, Berghel score and NIHSS score of observation group were significantly lower than those of control group (P<0.05). The total effective rate of observation group was 95.1%, significantly higher than 75.6% of control group (P<0.05). Conclusions Dual antiplatelet therapy with aspirin and clopidogrel for the treatment of acute cerebral infarction can effectively reduce the levels of serum CRP and fibrinogen. It is effective and safe, and worthy of clinical application.